Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
复制标题
乳腺癌中 c-erbB-2(neu) 或 c-myc 原癌基因的改变与不良的短期预后相关。
作者：
J. Varley;J. Swallow;W. J. Brammar;J. Whittaker;R. Walker
我们检测了41例乳腺癌、10例乳腺癌淋巴结转移、1例纤维肉瘤、10例良性纤维囊性乳腺和6例纤维腺瘤组织中c-myc、N-myc、L-myc、neu和N-ras的基因组结构。在所研究的任何样本中，我们都没有观察到N-myc或N-ras的变化。我们在一例浸润性导管癌的脱氧核糖核酸中看到了L=myc的2倍扩增，但在其他方面我们没有看到该基因的变化。22%的ID乳腺癌标本中有c-myc基因扩增。扩增水平从2倍到10倍不等。我们发现c-myc基因改变与非常差的短期预后之间存在显著的相关性(p<0.02)。19%的ID乳腺癌可见neu扩增，但扩增水平高于c-myc。Neu的改变也与不良的短期预后密切相关(p<0.0002)。最后，我们观察到良性纤维囊性乳腺病变的DNA中c-myc的扩增水平很低。这种病变表现出一些特征，那些被认为与乳腺癌风险增加有关的患者。
We have examined the genomic organisation of c-myc, N-myc, L-myc, neu and N-ras in tissue from 41 breast carcinomas, lymph node metastases from 10 of these carcinomas, one fibrosarcoma, 10 cases of benign fibrocystic breast and six fibroadenomas. We have not observed an alteration in either N-myc or N-ras in any of the samples studied. We have seen a 2-fold amplification of L=myc in DNA from one infiltrating ductal (ID) carcinoma, but otherwise we have seen no alterations to this gene. Amplification of c-myc was seen in 22% of ID breast carcinoma sample. Levels of amplification ranged from 2- to 10-fold. We have found a significant (p less than 0.02) correlation between an altered c-myc gene and a very poor short-term prognosis. Amplification of neu was seen in 19% of ID breast carcinomas, but the levels of amplification were higher than those seen for c-myc. Alterations to neu also correlated well with poor short-term prognosis (p less than 0.0002). Finally, we have observed a low level of amplification of c-myc in DNA from a benign fibrocystic breast lesion. This lesion exhibited some features characteristic of those thought to be associated with an increased risk of developing breast cancer.